|
|
 |
 |
|
 |
| |
|
| |
On July 1, 2010, ACT successfully completed raising
$10 million, which was six (6) months ahead of its planned schedule for
2010. Funds from this capital raise will be used diligently to advance
into Phase 1 human clinical trials one or more of the five (5) products
it has exclusively licensed from UofL's James Graham Brown Cancer Center.
ACT intends to efficiently deploy these funds to advance
one or more compounds from its product pipeline up to or
through Phase 1 human clinical trials and then explore
strategic partnering options with leading pharmaceutical
and biotechnology companies. |
|
 |
|
 |
|
 |
